EGFR and breast carcinoma: In this regard, agents targeting EGFR have also been extensively investigated in canine and feline cell lines of OSCC, OSA, TCC and mammary carcinoma, but only the use of EGF‐anthrax toxin has been reported in the clinical setting, for the treatment of canine invasive TCC.